Study:
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies
Rationale:
n/a
Purpose:
This is a Phase II, open-label, two strata, multicenter, prospective study of
plerixafor-mobilized HLA-identical sibling allografts in recipients with hematological
malignancies. This study will establish the safety and efficacy of subcutaneous plerixafor
for this purpose.
Study Status: Recruiting
Recruiting:
n/a
| Condition |
Intervention |
Phase |
For Donors:
Related Donors Donating PBSC to a Family Member
For Recipients:
Acute Myelogenous Leukemia
Acute Lymphoblastic Leukemia
Myelodysplastic Syndrome
Chronic Myelogenous Leukemia
Non-Hodgkin`s Lymphoma
Hodgkin`s Disease
Chronic Lymphocytic Leukemia |
Drug: Plerixafor |
Phase 2 |
Verified by
Center for International Blood and Marrow Transplant Research
May, 2013
Sponsored by: Center for International Blood and Marrow Transplant Research
Information provided by: Center for International Blood and Marrow Transplant Research
ClinicalTrials.gov identifier: NCT01696461
Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Cleveland Clinic
Cleveland, Ohio
United States
Steve Devine, MD., Principal Investigator